Ensem Therapeutics, Inc. USA General Counsel Steve Chen Invites You to the 2026 CBA-China Annual Conference in Wuxi

Chinese-American Biopharmaceutical Technology Association(Chinese Biopharmaceutical Association, abbreviated as CBA, official website: www.cba-usa.org) was founded in 1995. It is an independent, non-governmental, and non-profit professional industry organization, and also one of the leading Chinese-American biopharmaceutical technical associations in the United States. Since its establishment, the association has been committed to building a bridge for scientific exchange and innovative cooperation between the biopharmaceutical industries in China and the United States. It focuses on the biopharmaceutical field and promotes cross-border collaborative development within the industry.

The headquarters of CBA is located in Maryland, USA, with four major branches established in Boston, Philadelphia, Canada, and Suzhou, China, forming a global industry liaison network. Currently, the association boasts over 10,000 individual members and nearly a hundred institutional members, gathering top experts, industry elites, and high-quality enterprises from countries and regions around the world, including China, the United States, Europe, Canada, Australia, Singapore, and Japan, thus creating a diverse and high-level global biopharmaceutical professional community.

For 31 years, CBA has been forging ahead, steadfast in its mission to promote exchanges and cooperation among biopharmaceutical professionals and to facilitate the development of the global life sciences and health industry. It has been deeply committed to advancing industrial collaboration across countries and regions, with particularly remarkable achievements in strengthening U.S.-China biopharmaceutical commercial cooperation and building partnerships. The association is dedicated to creating a platform for talent cultivation and entrepreneur incubation, fostering a collaborative and innovative industrial ecosystem for biopharmaceutical companies and research institutions to achieve mutual benefits, providing solid support for innovation and entrepreneurship within the industry. Over the years, CBA has continuously organized and co-hosted a variety of activities with various sectors, including the U.S.-China annual industry conferences, specialized workshops, professional seminars, and industry networking events. These efforts have established a comprehensive professional platform that integrates knowledge sharing, cutting-edge technology learning, industry trend leadership, resource networking, and career development empowerment, playing a significant role in the global biopharmaceutical field. Relying on the selfless dedication of its members and the long-term support of sponsors from all sectors, the association has grown in size, and its influence within the industry continues to expand.

In 2024, CBA-China was officially established, initiated by several former core members of CBA and joined by many senior figures in China's pharmaceutical industry. It carries forward the core mission of CBA, fully promoting in-depth exchanges and cross-border cooperation among global biopharmaceutical professionals. It further deepens trade and technical collaboration between China and the U.S. in the biopharmaceutical industry, continuously serving as an incubator for talent and enterprises, and fostering a high-quality industrial environment that advances the synergy of industry, academia, and research. Relying on Ameripharm with PharmTech Consulting Co., Ltd., CBA-China conducts various industry conferences and exchange activities in compliance within China, achieving localized and standardized operations.

Since its establishment, CBA-China has achieved remarkable results, successfully hosting two consecutive CBA-CHINA annual conferences in Suzhou in 2024 and 2025, attracting over 20,000 participants in total. These two grand events brought together nearly a thousand top industry guests from home and abroad, including Nobel laureates, multiple academicians of the Chinese Academy of Sciences and Chinese Academy of Engineering, and senior executives from multinational pharmaceutical companies. The conferences have become a phenomenal benchmark meeting in China's biopharmaceutical field, creating a high-quality communication platform that gathers academic elites, business leaders, and representatives of government institutions. They have also become a core hub for industry knowledge sharing, technological innovation, resource integration, and career development.

After two years of in-depth exploration, adjustment, and沉淀, from 2025 to 2026, CBA-China will comprehensively expand and upgrade its executive team. Establishing the main theme of "Connection and Integration" for the year’s development, with an open and win-win attitude, it will join hands with colleagues from the global biopharmaceutical industry to move forward together. It will fully assist Chinese innovative drugs in going abroad and reaching the world, jointly promoting high-quality innovation and development of the global biopharmaceuticals industry.